key: cord-0857330-00i76dle
authors: Boven, A G; Kenyon, C; Colebunders, R
title: Ivermectin should not be recommended to treat SARS-CoV-2 infection
date: 2021-09-02
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab456
sha: 51983dba7b75e4fdbf71fefc882575fcf151c792
doc_id: 857330
cord_uid: 00i76dle

nan

The problem with most ivermectin trials carried is their small sample size (less than 500 participants) and poor quality which makes it difficult to interpret the results. This is illustrated by the fact that the risk for bias of the different studies is evaluated differently in the different reviews (see Table 1 ).

Since these five systematic reviews were published, the results of a new clinical trial has been published 7 . This trial was a well-designed, double-blind and placebo-controlled trial that enrolled 500 persons per arm. Currently, it is the second largest trial that assesses the effect of ivermectin on COVID-19 outcomes. Although still underpowered due to a lower percentage of events than expected, this trial did not detect a significant effect of ivermectin on preventing hospitalization nor the need for mechanical ventilatory support 7 . The only other randomized controlled trial considered to be at a low risk for bias in all the systematic reviews also found that ivermectin had no beneficial effect on time-to-recovery (Lopez-Medina et al., table 1). Both these trials were peer-reviewed and published in reputable journals. All the other trials were either much smaller, not placebo-controlled and/or not double-blinded. Furthermore 5 out of 11 studies included are unpublished and merely posted on pre-print websites (Table 1) . M a n u s c r i p t 3

The danger of including these studies is illustrated by the recent retraction of the Elgazzar et al. study from the preprint site which was hosting it following very serious allegations of scientific misconduct 8 . Of all the studies included in the Hill et al. review, this study had the biggest effect size. When this study, with a 90% reduction in mortality, is excluded from analysis, no beneficial effect of ivermectin is seen. We thus have two well conducted randomized controlled trials with a low risk of bias which show no effect of ivermectin and a number of other trials either unpublished or at a high risk of bias which show a beneficial effect of ivermectin. In this situation we consider it inappropriate to use meta-analysis methodology to pool these results. We should limit our evaluation of ivermectin to the evidence derived from high quality studies. Another high quality randomized controlled trial, the United Kingdom's Principle outpatient trial, has already enrolled 5000 patients in its ivermectin arm and results are expected soon 9 .

M a n u s c r i p t 4

In conclusion, based on four well conducted systematic reviews and the results of the two best-designed clinical trials so far 7 , we concur with most international COVID-19 guidelines that the current evidence does not support the use of ivermectin as treatment for COVID-19 infection.

Misinformation about the efficacy of ivermectin in COVID-19 infection should be countered. A paper such as the review by Kory et al. 6 is used by influencers and the social media to create confusion and increase the distrust of people in international evidence-based COVID-19 recommendations. What low and middle income countries need is more access to oxygen and COVID-19 vaccines, and not ivermectin.

It is now time to conduct trials for a condition for which ivermectin is most useful: onchocerciasis. There is a critical need for clinical trials to evaluate the safety of ivermectin for the treatment of children below the age of five years and for pregnant women. Lowering the age to treat children and allowing pregnant women to be treated with ivermectin, together with increasing the frequency of ivermectin distribution, could not only reduce the time to eliminate onchocerciasis but also prevent onchocerciasis-associated morbidities such as onchocerciasis-associated epilepsy 10 .

Desperate times: Dealers peddle Ivermectin as COVID-19 continues to rip through South Africa

Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection. Open Forum Infectious Diseases

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials

World Health Organization. Therapeutics and COVID-19: living guideline

Ivermectin and mortality in patients with COVID-19: A systematic review, meta-analysis, and meta-regression of randomized controlled trials

Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19

Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebocontrolled trial

Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns. The Guardian

Ivermectin to be investigated in adults aged 18+ as a possible treatment for COVID-19 in the PRINCIPLE trial

Safety of ivermectin during pregnancy

M a n u s c r i p t 5 Funding R Colebunders received funding from VLIRUOS (Flemish Interuniversity Council for University Development Cooperation), but this funder did not influence the writing of this paper in any way.A c c e p t e d M a n u s c r i p t 6